CND Life Sciences is a medical technology company that develops evidence-based tool to assist physicians in diagnosing synucleinopathy.
CND Life Sciences has raised $13.5M in total funding. The most recent round was Private Equity. The last funding was announced in August 2026.
CND Life Sciences's investors include Michael J. Fox Foundation, LabCorp, MBX Capital, National Institutes of Health, BlueStone Venture Partners.
CND Life Sciences is headquartered in Scottsdale, United States.
CND Life Sciences is a medical technology company that develops evidence-based tool to assist physicians in diagnosing synucleinopathy.
CND Life Sciences is at the Private Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CND Life Sciences — Funding & Investors." VCBacked, August 4, 2026, https://www.vcbacked.co/company/cnd-life-sciences. Accessed October 17, 2026.
VCBacked. (2026). CND Life Sciences — Funding & Investors. Retrieved October 17, 2026, from https://www.vcbacked.co/company/cnd-life-sciences
{{cite web |title=CND Life Sciences — Funding & Investors |url=https://www.vcbacked.co/company/cnd-life-sciences |website=VCBacked |access-date=October 17, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated